Publications

Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD

Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.

Development and Validation of the Mastocytosis Quality of Life questionnaire: MC-QoL

Filename 240. Siebenhaar et al., Mastocytosis QoL, ALLERGY 2016.pdf
Filesize 240 KB
Version o.240
Date added July 30, 2020
Downloaded 0 times
Category Original Work
Tags health, instrument, mastocytosis, Quality of life, Questionnaire
Authors Siebenhaar, F., von Tschirnhaus, E., Hartmann, K., Rabenhorst, A., Staubach, P., Peveling-Oberhag, A., Wagner, N., Martus, P., Carter, M. C., Metcalfe, D. D., Church, M. K., Maurer, M. and Weller, K.
Citation Siebenhaar, F., von Tschirnhaus, E., Hartmann, K., Rabenhorst, A., Staubach, P., Peveling-Oberhag, A., Wagner, N., Martus, P., Carter, M. C., Metcalfe, D. D., Church, M. K., Maurer, M. and Weller, K.: Development and Validation of the Mastocytosis Quality of Life questionnaire: MC-QoL. Allergy 2016: 71; 869-877.
Corresponding authors Siebenhaar, F.
DocNum O.240
DocType PDF
Edition; Page 71; 869-877
IF 7.36
Publisher Allergy
ReleaseDate 2016

Background: Mastocytosis is a heterogeneous disease characterized by a clonal expansion of mast cells in various organs. The vast majority of patients affected suffer from signs and symptoms caused by mediator release from mast cells. Although the disease burden is high, there is currently no specific instrument to measure health-related quality of life (HRQoL) impairment in patients with mastocytosis.

Objective: The aim of this study was to develop and validate a disease-specifictool to assess HRQoL impairment in patients with cutaneous and indolent sys-temic mastocytosis, the Mastocytosis Quality of Life Questionnaire (MC-QoL).

Methods: Sixty-two potential MC-QoL items were developed in a combined approach consisting of semi-structured patient interviews, expert input and literature research. Item selection was performed by impact analysis with 76 patients and a final review for face validity. The resulting MC-QoL was tested for validity, reliability and influence factors. In parallel, an US American-English version ofthe MC-QoL was developed.

Results: A total of 158 patients (41 CM, 41 MIS and 76 ISM) took part in theMC-QoL validation study. The final 27-item questionnaire was found to have a four-domain structure (‘symptoms’, ‘emotions’, ‘social life/functioning’ and ‘skin’), a valid total score and an excellent test–retest reliability. Multiple regression analysis revealed disease duration, but not age, gender or skin involvement to be a significant determinant of HRQoL impairment in mastocytosis.

Conclusions:The MC-QoL is the first disease-specific HRQoL questionnaire for adult patients with cutaneous and indolent systemic mastocytosis. This short, validated and reliable instrument will serve as a valuable tool in future clinical stud-ies and in routine patient care.

(Last update: 02.2021)

Number of publications (original work and reviews) in peer-reviewed journals: 601
Number of original publications in peer-reviewed journals: 432
Number of reviews in peer-reviewed journals: 169
Cumulative IF of publications (original work & reviews) in peer-reviewed journals: 3326,21
Cumulative IF for original publications in peer-reviewed journals: 2659,47
Cumulative IF for reviews in peer-reviewed journals: 666,74
Citations, Hirsch index: (view on Web of Science) 24104